Mucus- and pH-mediated controlled release of core-shell chitosan nanoparticles in the gastrointestinal tract for diabetes treatment

References

• Dai R, Liu R-M, Xiao J-h Research progress on hypoglycemic effect and its mechanism of action of medicinal fungal polysaccharides. Zhongguo Zhong Yao Za Zhi. 2015;40(2):174–179.
   PubMedGoogle Scholar
• Seo MH, Lee WY, Kim SS, Committee of Clinical Practice Guidelines, Korean Society for the Study of Obesity (KSSO), et al. Corrigendum: 2018 Korean society for the study of obesity guideline for the management of obesity in Korea. J Obes Metab Syndr. 2019;28(2):143.
   PubMed Web of Science ®Google Scholar
• Yoon K-H, Lee J-H, Kim J-W, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368(9548):1681–1688.
   PubMed Web of Science ®Google Scholar
• Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117–124.
   PubMed Web of Science ®Google Scholar
• Kwon KC, Verma D, Singh ND, et al. Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. Adv Drug Deliv Rev. 2013;65(6):782–799.
   PubMed Web of Science ®Google Scholar
• Ahad A, Al-Saleh AA, Akhtar N, et al. Transdermal delivery of antidiabetic drugs: formulation and delivery strategies. Drug Discov Today. 2015;20(10):1217–1227.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu X, Meng L, et al. Thiolated Eudragit nanoparticles for oral insulin delivery: preparation, characterization and in vivo evaluation. Int J Pharm. 2012;436(1-2):341–350.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li P, Truong-Dinh Tran T, et al. Manufacturing techniques and surface engineering of polymer based nanoparticles for targeted drug delivery to cancer. Nanomaterials (Basel). 2016;6(2):26.
   PubMedGoogle Scholar
• Dong F, Li S. Wound dressings based on chitosan-dialdehyde cellulose nanocrystals-silver nanoparticles: mechanical strength, antibacterial activity and cytotoxicity. Polymers. 2018;10(6):673.
   PubMed Web of Science ®Google Scholar
• Chen MC, Sonaje K, Chen KJ, et al. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials. 2011;32(36):9826–9838.
   PubMed Web of Science ®Google Scholar
• Yeh TH, Hsu LW, Tseng MT, et al. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials. 2011;32(26):6164–6173.
   PubMed Web of Science ®Google Scholar
• Nagarpita MV, Roy P, Shruthi SB, et al. Synthesis and swelling characteristics of chitosan and CMC grafted sodium acrylate-co-acrylamide using modified nanoclay and examining its efficacy for removal of dyes. Int J Biol Macromol. 2017;102:1226–1240.
   PubMed Web of Science ®Google Scholar
• Fasano A, Uzzau S. Modulation of intestinal tight junctions by zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J Clin Invest. 1997;99(6):1158–1164.
   PubMed Web of Science ®Google Scholar
• Deshpande NP, Wilkins MR, Castano-Rodriguez N, et al. Campylobacter concisus pathotypes induce distinct global responses in intestinal epithelial cells. Sci Rep. 2016;6:34288.
   PubMed Web of Science ®Google Scholar
• Song KH, Fasano A, Eddington ND. Effect of the six-mer synthetic peptide (AT1002) fragment of zonula occludens toxin on the intestinal absorption of cyclosporin A. Int J Pharm. 2008;351(1-2):8–14.
   PubMedGoogle Scholar
• Ijioma SN, Nwaogazi EN, Nwankwo AA, et al. Histological exhibition of the gastroprotective effect of Moringa oleifera leaf extract. Comp Clin Path. 2018;27(2):327–332.
   PubMedGoogle Scholar
• Lieleg O, Vladescu I, Ribbeck K. Characterization of particle translocation through mucin hydrogels. Biophys J. 2010;98(9):1782–1789.
   PubMed Web of Science ®Google Scholar
• Sakuma S, Sudo R, Suzuki N, et al. Mucoadhesion of polystyrene nanoparticles having surface hydrophilic polymeric chains in the gastrointestinal tract. Int J Pharm. 1999;177(2):161–172.
   PubMed Web of Science ®Google Scholar
• Yu M, Wang J, Yang Y, et al. Rotation-facilitated rapid transport of nanorods in mucosal tissues. Nano Lett. 2016;16(11):7176–7182.
   PubMed Web of Science ®Google Scholar
• Guan M, Zhou Y, Zhu QL, et al. N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy. Nanomedicine. 2012;8(7):1172–1181.
   PubMed Web of Science ®Google Scholar
• Baharifar H, Khoobi M, Bidgoli SA, et al. Preparation of PEG-grafted chitosan/streptokinase nanoparticles to improve biological half-life and reduce immunogenicity of the enzyme. Int J Biol Macromol. 2020;143:181–189.
   PubMed Web of Science ®Google Scholar
• Fan W, Xia D, Zhu Q, et al. Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. Biomaterials. 2018;151:13–23.
   PubMed Web of Science ®Google Scholar
• Xu Q, Ensign LM, Boylan NJ, et al. Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo. ACS Nano. 2015;9(9):9217–9227.
   PubMed Web of Science ®Google Scholar
• Pardo-Camacho C, Gonzalez-Castro AM, Rodino-Janeiro BK, et al. Epithelial immunity: priming defensive responses in the intestinal mucosa. Am J Physiol Gastrointest Liver Physiol. 2018;314(2):G247–G255.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Chakraborty S, Bhattacharya S, et al. pH-sensitive chitosan/alginate core-shell nanoparticles for efficient and safe oral insulin delivery. Int J Biol Macromol. 2015;72:640–648.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Sarkar K, Chakraborty M, et al. Oral insulin delivery by self-assembled chitosan nanoparticles: in vitro and in vivo studies in diabetic animal model. Mater Sci Eng C Mater Biol Appl. 2013;33(1):376–382.
   PubMed Web of Science ®Google Scholar
• Pridgen EM, Alexis F, Farokhzad OC. Polymeric nanoparticle drug delivery technologies for oral delivery applications. Expert Opin Drug Deliv. 2015;12(9):1459–1473.
   PubMed Web of Science ®Google Scholar
• Song Y, Shi Y, Zhang L, et al. Synthesis of CSK-DEX-PLGA nanoparticles for the oral delivery of exenatide to improve its mucus penetration and intestinal absorption. Mol Pharm. 2019;16(2):518–532.
   PubMedGoogle Scholar
• Hall MJ, Adin CA, Borin-Crivellenti S, et al. Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats. Domest Anim Endocrinol. 2015;51:114–121.
   PubMed Web of Science ®Google Scholar
• Klein DJ, Battelino T, Chatterjee DJ, NN2211-1800 Study Group, et al. Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Technol Ther. 2014;16(10):679–687.
   PubMed Web of Science ®Google Scholar
• Meier JJ, Rosenstock J, Hincelin-Mery A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38(7):1263–1273.
   PubMed Web of Science ®Google Scholar
• Jacobsen LV, Flint A, Olsen AK, et al. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2016;55(6):657–672.
   PubMed Web of Science ®Google Scholar